Provention Bio

Provention Bio FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Provention Bio (PRVB) as of Oct 26, 2026 is 67.10 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.19 % — a change of -20.30% (lower).

FCF Conversion

67.10 %

YoY

-20.30%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Provention Bio is 2022 67.10 % . FCF Conversion Rate (FCF/EBITDA) of Provention Bio was 2021 84.19 % . It decreases by -20.30% lower compared to the previous year.

The Provention Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
2,964.00 USD
Jan 1, 2017
65.61 USD
Jan 1, 2018
89.71 USD
Jan 1, 2019
88.10 USD
Jan 1, 2020
78.56 USD
Jan 1, 2021
84.19 USD
Jan 1, 2022
67.10 USD
The Provention Bio FCF Conversion history
YEARFCF ConversionYoY
67.10 %-20.30%
84.19 %+7.17%
78.56 %-10.83%
88.10 %-1.79%
89.71 %+36.72%
65.61 %-97.79%
2,964.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Provention Bio Stock analysis

What does Provention Bio do? Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Provention Bio stock

FCF Conversion Rate (FCF/EBITDA) of Provention Bio is 67.10 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Provention Bio changed from 84.19 % to 67.10 %, representing a -20.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Provention Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Provention Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Provention Bio

All Key Metrics — Provention Bio